Medical and Molecular Microbiology, Faculty of Science and Medicine, University of Fribourg, Fribourg, Switzerland.
Swiss National Reference Center for Emerging Antibiotic Resistance (NARA), University of Fribourg, Fribourg, Switzerland.
J Antimicrob Chemother. 2022 Nov 28;77(12):3456-3461. doi: 10.1093/jac/dkac340.
Cefiderocol is among the latest generation of commercialized antibiotics against a large variety of MDR Gram-negative bacteria including carbapenem-resistant Enterobacterales and non-fermenters such as Pseudomonas aeruginosa and Acinetobacter baumannii. Cefiderocol susceptibility testing, a key element for implementing rapidly a cefiderocol-based treatment, might be still challenging.
To develop a rapid culture-based test, Rapid Cefiderocol NP test, for the identification of cefiderocol resistance among MDR Enterobacterales.
The Rapid Cefiderocol NP test is based on glucose metabolization when bacterial growth occurs and the detection of bacterial growth in the presence of cefiderocol at 64 mg/L using iron-depleted CAMHB. Bacterial growth is visually detectable by a red-to-yellow colour change of red phenol, a pH indicator. A total of 74 clinical enterobacterial isolates from various clinical sources and of worldwide origin, among which 42 isolates were cefiderocol resistant, were used to evaluate the test performance.
The sensitivity and specificity of the test were found to be 98% and 91%, respectively, by comparison with the reference broth microdilution (BMD) method. All positive results were obtained within 3 h after incubation at 35°C ± 2°C, that is a gain of time of ca. 18 h (1 day) compared with currently used techniques for susceptibility testing (BMD method).
This novel test is rapid, highly sensitive, specific, easily interpretable, and easy to implement in routine microbiology laboratories. Such a test may rapidly and accurately provide the information needed for the implementation of adequate cefiderocol-based treatment.
头孢他啶罗利是最新一代商业化抗生素之一,可对抗多种 MDR 革兰氏阴性菌,包括耐碳青霉烯类肠杆菌科细菌和非发酵菌,如铜绿假单胞菌和鲍曼不动杆菌。头孢他啶罗利药敏试验是实施基于头孢他啶罗利治疗的关键要素,可能仍然具有挑战性。
开发一种快速基于培养的检测方法,即 Rapid Cefiderocol NP 试验,用于鉴定 MDR 肠杆菌科细菌中的头孢他啶罗利耐药性。
Rapid Cefiderocol NP 试验基于细菌生长时的葡萄糖代谢以及在 64mg/L 头孢他啶罗利存在下使用缺铁 CAMHB 检测细菌生长。当存在细菌生长时,红色酚会发生颜色变化,由红色变为黄色,这是一种 pH 指示剂,肉眼可检测到细菌生长。总共使用了 74 株来自各种临床来源和全球来源的临床肠杆菌属分离株来评估该试验的性能,其中 42 株分离株对头孢他啶罗利耐药。
通过与参考肉汤微量稀释(BMD)方法比较,该试验的灵敏度和特异性分别为 98%和 91%。在 35°C±2°C 孵育 3 小时后,即可获得所有阳性结果,与目前用于药敏试验的技术(BMD 方法)相比,可节省约 18 小时(1 天)的时间。
这种新的检测方法快速、高度敏感、特异、易于解释且易于在常规微生物学实验室中实施。这种检测方法可以快速准确地提供实施基于头孢他啶罗利的充分治疗所需的信息。